N
NovaBay Pharmaceuticals Inc
XBER:B9P
NovaBay Pharmaceuticals Inc
XBER:B9P
Price:
0.114
EUR
-11.63%
Market Closed
Market Cap:
€480.5k
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
NovaBay Pharmaceuticals Inc
XBER:B9P
|
US |
|
C
|
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
|
TW |
|
Growthpoint Properties Australia Ltd
ASX:GOZ
|
AU |
|
A
|
Ability Enterprise Co Ltd
TWSE:2374
|
TW |
|
Broedrene A & O Johansen A/S
CSE:AOJ B
|
DK |
|
Y
|
YY Group Holding Ltd
NASDAQ:YYGH
|
SG |
|
SK Hynix Inc
KRX:000660
|
KR |
Income Statement
Earnings Waterfall
NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals Inc
Income Statement
NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals Inc
Currency: USD
| Mar-2014 | Jun-2014 | Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||||||||||||||||
| Revenue |
3
N/A
|
2
-27%
|
1
-47%
|
1
-2%
|
1
+24%
|
2
+68%
|
3
+48%
|
4
+35%
|
6
+27%
|
7
+30%
|
9
+31%
|
12
+26%
|
14
+17%
|
15
+11%
|
16
+4%
|
18
+14%
|
17
-4%
|
16
-8%
|
15
-6%
|
13
-18%
|
11
-12%
|
10
-9%
|
9
-15%
|
7
-23%
|
7
+6%
|
9
+31%
|
10
+6%
|
10
+2%
|
10
-1%
|
9
-10%
|
9
+1%
|
8
-6%
|
11
+32%
|
12
+6%
|
13
+13%
|
14
+7%
|
14
-1%
|
15
+7%
|
15
-4%
|
15
+1%
|
14
-3%
|
|
| Gross Profit | ||||||||||||||||||||||||||||||||||||||||||
| Cost of Revenue |
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
(3)
|
(3)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(4)
|
(4)
|
(4)
|
(4)
|
(3)
|
(3)
|
(2)
|
(4)
|
(5)
|
(6)
|
(7)
|
(6)
|
(7)
|
(7)
|
(7)
|
(6)
|
|
| Gross Profit |
2
N/A
|
2
-29%
|
1
-54%
|
1
-30%
|
1
+40%
|
1
+81%
|
2
+57%
|
3
+37%
|
4
+23%
|
5
+37%
|
7
+37%
|
9
+31%
|
11
+21%
|
13
+11%
|
13
+6%
|
15
+16%
|
15
-3%
|
14
-7%
|
13
-5%
|
11
-16%
|
9
-14%
|
9
-10%
|
7
-19%
|
5
-30%
|
5
+3%
|
6
+11%
|
6
+8%
|
6
-1%
|
6
+1%
|
6
0%
|
6
-1%
|
6
+1%
|
7
+13%
|
7
-1%
|
7
+13%
|
8
+4%
|
8
+2%
|
8
+6%
|
8
-6%
|
8
+1%
|
8
-2%
|
|
| Operating Income | ||||||||||||||||||||||||||||||||||||||||||
| Operating Expenses |
(19)
|
(17)
|
(18)
|
(17)
|
(18)
|
(20)
|
(22)
|
(24)
|
(25)
|
(24)
|
(22)
|
(20)
|
(22)
|
(22)
|
(23)
|
(23)
|
(21)
|
(20)
|
(19)
|
(19)
|
(19)
|
(17)
|
(16)
|
(14)
|
(12)
|
(12)
|
(13)
|
(12)
|
(12)
|
(13)
|
(13)
|
(13)
|
(16)
|
(17)
|
(16)
|
(15)
|
(22)
|
(21)
|
(21)
|
(13)
|
(16)
|
|
| Selling, General & Administrative |
(7)
|
(6)
|
(7)
|
(8)
|
(10)
|
(12)
|
(15)
|
(18)
|
(19)
|
(19)
|
(20)
|
(19)
|
(21)
|
(22)
|
(23)
|
(22)
|
(21)
|
(20)
|
(19)
|
(19)
|
(19)
|
(17)
|
(15)
|
(14)
|
(12)
|
(12)
|
(13)
|
(12)
|
(12)
|
(13)
|
(13)
|
(13)
|
(16)
|
(17)
|
(16)
|
(15)
|
(15)
|
(14)
|
(15)
|
(13)
|
(13)
|
|
| Research & Development |
(12)
|
(11)
|
(11)
|
(10)
|
(9)
|
(8)
|
(7)
|
(6)
|
(5)
|
(4)
|
(2)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(7)
|
(7)
|
(7)
|
0
|
(3)
|
|
| Operating Income |
(16)
N/A
|
(16)
+2%
|
(17)
-7%
|
(17)
0%
|
(17)
-3%
|
(19)
-6%
|
(20)
-7%
|
(21)
-6%
|
(21)
+0%
|
(18)
+13%
|
(15)
+18%
|
(11)
+27%
|
(10)
+7%
|
(10)
+4%
|
(10)
-1%
|
(7)
+26%
|
(6)
+19%
|
(6)
-5%
|
(6)
+6%
|
(8)
-34%
|
(9)
-20%
|
(9)
+7%
|
(9)
+1%
|
(9)
-7%
|
(7)
+26%
|
(7)
+5%
|
(7)
-5%
|
(6)
+7%
|
(6)
+0%
|
(7)
-12%
|
(7)
-3%
|
(7)
+8%
|
(10)
-42%
|
(10)
-3%
|
(8)
+18%
|
(8)
+6%
|
(14)
-79%
|
(13)
+6%
|
(14)
-5%
|
(5)
+63%
|
(8)
-66%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||
| Interest Income Expense |
0
|
1
|
2
|
2
|
1
|
0
|
1
|
2
|
2
|
1
|
(1)
|
(2)
|
(2)
|
(2)
|
(0)
|
(0)
|
0
|
1
|
1
|
1
|
1
|
(1)
|
1
|
0
|
0
|
(2)
|
(6)
|
(5)
|
0
|
0
|
0
|
5
|
7
|
7
|
7
|
4
|
2
|
2
|
2
|
0
|
1
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
(7)
|
0
|
0
|
0
|
(3)
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(1)
|
(0)
|
1
|
1
|
(5)
|
0
|
0
|
(2)
|
(2)
|
(2)
|
(2)
|
(0)
|
(0)
|
(1)
|
(2)
|
(2)
|
(3)
|
|
| Pre-Tax Income |
(16)
N/A
|
(15)
+7%
|
(15)
-3%
|
(15)
-2%
|
(16)
-7%
|
(18)
-12%
|
(19)
-6%
|
(19)
+1%
|
(19)
-2%
|
(17)
+11%
|
(16)
+9%
|
(13)
+16%
|
(12)
+8%
|
(11)
+8%
|
(10)
+12%
|
(7)
+25%
|
(6)
+25%
|
(5)
+3%
|
(4)
+17%
|
(7)
-46%
|
(9)
-31%
|
(10)
-11%
|
(8)
+13%
|
(10)
-17%
|
(7)
+27%
|
(9)
-28%
|
(12)
-33%
|
(11)
+8%
|
(11)
+1%
|
(8)
+24%
|
(7)
+11%
|
(6)
+22%
|
(4)
+24%
|
(5)
-7%
|
(3)
+46%
|
(11)
-313%
|
(12)
-15%
|
(12)
+1%
|
(14)
-13%
|
(10)
+30%
|
(11)
-14%
|
|
| Net Income | ||||||||||||||||||||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
13
|
0
|
13
|
13
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(16)
|
(15)
|
(15)
|
(15)
|
(16)
|
(18)
|
(19)
|
(19)
|
(19)
|
(17)
|
(16)
|
(13)
|
(12)
|
(11)
|
(10)
|
5
|
7
|
7
|
8
|
(7)
|
(9)
|
(10)
|
(8)
|
(10)
|
(7)
|
(9)
|
(12)
|
(11)
|
(11)
|
(8)
|
(7)
|
(6)
|
(4)
|
(5)
|
(3)
|
(11)
|
(12)
|
(12)
|
(14)
|
(10)
|
(11)
|
|
| Net Income (Common) |
(16)
N/A
|
(15)
+7%
|
(15)
-3%
|
(15)
-2%
|
(16)
-7%
|
(18)
-12%
|
(19)
-6%
|
(19)
+1%
|
(19)
-2%
|
(17)
+11%
|
(16)
+9%
|
(13)
+16%
|
(12)
+8%
|
(11)
+8%
|
(10)
+12%
|
(7)
+25%
|
(6)
+25%
|
(5)
+3%
|
(4)
+17%
|
(7)
-46%
|
(9)
-31%
|
(10)
-11%
|
(8)
+13%
|
(10)
-27%
|
(8)
+25%
|
(10)
-25%
|
(13)
-30%
|
(11)
+14%
|
(11)
+1%
|
(8)
+24%
|
(7)
+11%
|
(7)
+12%
|
(5)
+21%
|
(5)
-6%
|
(9)
-64%
|
(16)
-82%
|
(18)
-10%
|
(20)
-10%
|
(16)
+20%
|
(17)
-6%
|
(19)
-11%
|
|
| EPS (Diluted) |
-312.2
N/A
|
-241.66
+23%
|
-247.83
-3%
|
-253.16
-2%
|
-271.16
-7%
|
-227.74
+16%
|
-213.77
+6%
|
-237.12
-11%
|
-161.75
+32%
|
-81.95
+49%
|
-50.67
+38%
|
-48.7
+4%
|
-27.47
+44%
|
-25.31
+8%
|
-22.38
+12%
|
-16.81
+25%
|
-11.8
+30%
|
-11.02
+7%
|
-9.16
+17%
|
-13.64
-49%
|
-17.53
-29%
|
-17.98
-3%
|
-12.53
+30%
|
-16.91
-35%
|
-9.85
+42%
|
-11.29
-15%
|
-11.2
+1%
|
-11.02
+2%
|
-9.21
+16%
|
-6.27
+32%
|
-5.79
+8%
|
-5.26
+9%
|
-3.6
+32%
|
-3.6
N/A
|
-5.59
-55%
|
-10.1
-81%
|
-8.77
+13%
|
-6.21
+29%
|
-3.35
+46%
|
-138.65
-4 039%
|
-26.32
+81%
|
|
Switch to:
Switch to:
See Also
Discover More
